Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 21.11% is in line with its 5-year average of 21.13%, around the middle of its 5-year range (-1.52%–46.54%).
As of the fiscal period ended Tuesday, March 31, 2026. 0.43% above its 12-month average of 21.02%.
Reported quarterly profit margin; no daily interpolation.
NET PROFIT MARGIN
21.11%
NET PROFIT MARGIN AVG TTM
21.02%
NET PROFIT MARGIN AVG 3Y
19.49%
NET PROFIT MARGIN AVG 5Y
21.13%
NET PROFIT MARGIN AVG 10Y
27.71%
NET PROFIT MARGIN AVG 15Y
28.49%
NET PROFIT MARGIN AVG 20Y
28.64%
CURRENT VS TTM AVG
+0.43%
CURRENT VS 3Y AVG
+8.31%
CURRENT VS 5Y AVG
-0.09%
CURRENT VS 10Y AVG
-23.83%
CURRENT VS 15Y AVG
-25.91%
CURRENT VS 20Y AVG
-26.31%
SECTOR MEDIAN · HEALTHCARE
10.44%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+102.17%
vs the sector median at left
Market Cap
$211.18B
Net Profit Margin
15.06%
TTM Avg
14.95%
3Y Avg
14.84%
5Y Avg
16.47%
Market Cap
$216.72B
Net Profit Margin
37.14%
TTM Avg
33.96%
3Y Avg
33.83%
5Y Avg
33.74%
Market Cap
$179.58B
Net Profit Margin
11.65%
TTM Avg
23.34%
3Y Avg
19.20%
5Y Avg
17.71%
Market Cap
$160.55B
Net Profit Margin
30.99%
TTM Avg
15.29%
3Y Avg
17.07%
5Y Avg
15.27%
Market Cap
$262.31B
Net Profit Margin
17.19%
TTM Avg
15.23%
3Y Avg
12.72%
5Y Avg
10.53%
Market Cap
$137.47B
Net Profit Margin
0.72%
TTM Avg
0.84%
3Y Avg
1.34%
5Y Avg
1.79%
Market Cap
$134.62B
Net Profit Margin
15.95%
TTM Avg
15.52%
3Y Avg
19.51%
5Y Avg
19.37%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amgen Inc. (AMGN) | $202.95B | 21.11% | 21.02% | 19.49% | 21.13% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $211.18B | 15.06% | 14.95% | 14.84% | 16.47% |
| Novo Nordisk A/S (NVO)vs › | $216.72B | 37.14% | 33.96% | 33.83% | 33.74% |
| Abbott Laboratories (ABT)vs › | $179.58B | 11.65% | 23.34% | 19.20% | 17.71% |
| Gilead Sciences, Inc. (GILD)vs › | $160.55B | 30.99% | 15.29% | 17.07% | 15.27% |
| AstraZeneca PLC (AZN)vs › | $262.31B | 17.19% | 15.23% | 12.72% | 10.53% |
| Pfizer Inc. (PFE)vs › | $139.86B | 11.83% | 12.51% | 14.97% | 18.18% |
| CVS Health Corp. (CVS)vs › | $137.47B | 0.72% | 0.84% | 1.34% | 1.79% |
| Danaher Corporation (DHR)vs › | $134.62B | 15.95% | 15.52% | 19.51% | 19.37% |
| Bristol-Myers Squibb Company (BMY)vs › | $126.79B | 15.01% | -1.95% | 6.91% | 3.59% |
Operating Margin
31.6%
Net Profit Margin
21.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 21.11% |
| 2025-12-31 | 13.47% |
| 2025-09-30 | 33.65% |
| 2025-06-30 | 15.62% |
| 2025-03-31 | 21.23% |
| 2024-12-31 | 6.90% |
| 2024-09-30 | 33.28% |
| 2024-06-30 | 8.89% |
| 2024-03-31 | -1.52% |
| 2023-12-31 | 9.36% |
| 2023-09-30 | 25.06% |
| 2023-06-30 | 19.74% |
| 2023-03-31 | 46.54% |
| 2022-12-31 | 23.63% |
| 2022-09-30 | 32.22% |
| 2022-06-30 | 19.97% |
| 2022-03-31 | 23.66% |
| 2021-12-31 | 27.74% |
| 2021-09-30 | 28.09% |
| 2021-06-30 | 7.11% |
| 2021-03-31 | 27.89% |
| 2020-12-31 | 24.34% |
| 2020-09-30 | 31.47% |
| 2020-06-30 | 29.05% |
| 2020-03-31 | 29.62% |
| 2019-12-31 | 27.48% |
| 2019-09-30 | 34.30% |
| 2019-06-30 | 37.11% |
| 2019-03-31 | 35.85% |
| 2018-12-31 | 30.95% |
| 2018-09-30 | 31.49% |
| 2018-06-30 | 37.89% |
| 2018-03-31 | 41.61% |
| 2017-12-31 | -73.49% |
| 2017-09-30 | 35.01% |
| 2017-06-30 | 37.02% |
| 2017-03-31 | 37.90% |
| 2016-12-31 | 32.44% |
| 2016-09-30 | 34.71% |
| 2016-06-30 | 32.88% |
| 2016-03-31 | 34.38% |
| 2015-12-31 | 32.51% |
| 2015-09-30 | 32.55% |
| 2015-06-30 | 30.78% |
| 2015-03-31 | 32.25% |
| 2014-12-31 | 24.27% |
| 2014-09-30 | 24.73% |
| 2014-06-30 | 29.86% |
| 2014-03-31 | 23.73% |
| 2013-12-31 | 20.38% |
| 2013-09-30 | 28.81% |
| 2013-06-30 | 26.89% |
| 2013-03-31 | 33.84% |
| 2012-12-31 | 17.82% |
| 2012-09-30 | 25.63% |
| 2012-06-30 | 28.28% |
| 2012-03-31 | 29.25% |
| 2011-12-31 | 23.51% |
| 2011-09-30 | 11.51% |
| 2011-06-30 | 29.55% |
| 2011-03-31 | 30.36% |
| 2010-12-31 | 26.61% |
| 2010-09-30 | 32.39% |
| 2010-06-30 | 31.60% |
| 2010-03-31 | 32.49% |
| 2009-12-31 | 24.44% |
| 2009-09-30 | 36.36% |
| 2009-06-30 | 34.18% |
| 2009-03-31 | 30.80% |
| 2008-12-31 | 25.62% |
| 2008-09-30 | 29.88% |
| 2008-06-30 | 25.00% |
| 2008-03-31 | 31.44% |
| 2007-12-31 | 22.30% |
| 2007-09-30 | 5.57% |
| 2007-06-30 | 27.33% |
| 2007-03-31 | 30.13% |
| 2006-12-31 | 21.72% |
| 2006-09-30 | 30.51% |
| 2006-06-30 | 0.39% |
| 2006-03-31 | 31.12% |
| 2005-12-31 | 25.19% |
| 2005-09-30 | 30.66% |
| 2005-06-30 | 32.44% |
| 2005-03-31 | 30.14% |
| 2004-12-31 | 23.69% |
| 2004-09-30 | 8.70% |
| 2004-06-30 | 28.94% |
| 2004-03-31 | 29.46% |
| 2003-12-31 | 23.31% |
| 2003-09-30 | 27.73% |
| 2003-06-30 | 29.75% |
| 2003-03-31 | 28.01% |
| 2002-12-31 | 25.84% |
| 2002-09-30 | -173.52% |
| 2002-06-30 | 35.27% |
